Piper Sandler lowered the firm’s price target on Health Catalyst to $15 from $17 and keeps an Overweight rating on the shares. Health Catalyst’s results were overshadowed by delayed Tech-Enabled Managed Services deals and an outlook for FY24 revenue that fell short of consensus estimates, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HCAT:
- Health Catalyst Executive Team Undergoes Major Reshuffle
- Health Catalyst Reports Fourth Quarter and Year End 2023 Results
- Health Catalyst’s Abe Health Registry receives QPP approval
- Health Catalyst to Announce Fourth Quarter and Full Year 2023 Operating Results and Host Conference Call on Thursday, February 22, 2024
- Tesla downgraded, Coinbase upgraded: Wall Street’s top analyst calls